SCHEMBL4407274

SCHEMBL4407274

Cc1c(CCC(=O)O)c[nH]c1/C=C1\C(=O)Nc2cc(Cl)ccc21

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ZAP70 P43403 3/20 0.85
PDGFRB P09619 16/20 0.75
FGFR1 P11362 15/20 0.75
KDR P35968 15/20 0.75
EGFR P00533 6/20 0.75
AKT2 P31751 1/20 0.65
FLT1 P17948 2/20 0.54
SRC P12931 1/20 0.54
AURKA O14965 1/20 0.49
GAK O14976 1/20 0.49
RPS6KA5 O75582 1/20 0.49
RPS6KA4 O75676 1/20 0.49
LATS1 O95835 1/20 0.49
RET P07949 1/20 0.49
CSNK2A2 P19784 1/20 0.49
MAP2K2 P36507 1/20 0.49
FLT3 P36888 1/20 0.49
MAP2K1 Q02750 1/20 0.49
MAP4K2 Q12851 1/20 0.49
STK4 Q13043 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4407278 1.00 ZAP70 (0.85) ZAP70PDGFRBFGFR1KDREGFR
SCHEMBL7814700 0.96 ZAP70 (0.79) ZAP70PDGFRBFGFR1KDREGFR
SCHEMBL7814702 0.96 ZAP70 (0.79) ZAP70PDGFRBFGFR1KDREGFR
SCHEMBL4414161 0.92 ZAP70 (1.00) ZAP70PDGFRBFGFR1KDREGFR
SCHEMBL4414158 0.92 ZAP70 (1.00) ZAP70PDGFRBFGFR1KDREGFR
SCHEMBL4413147 0.89 PDGFRB (0.77) ZAP70PDGFRBFGFR1KDREGFR
SCHEMBL4413149 0.89 PDGFRB (0.77) ZAP70PDGFRBFGFR1KDREGFR
SCHEMBL4406627 0.88 PDGFRB (0.75) ZAP70PDGFRBFGFR1KDREGFR
SCHEMBL4406624 0.88 PDGFRB (0.75) ZAP70PDGFRBFGFR1KDREGFR
SCHEMBL7814704 0.87 ZAP70 (0.65) ZAP70PDGFRBFGFR1KDREGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030105151-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. 2003-06-05 US claimed
EP-2020408-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors Sugen, Inc. (US) 2009-02-04 EP disclosed
US-7119090-B2 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. (US) 2006-10-10 US disclosed
US-6878733-B1 Formulations for pharmaceutical agents ionizable as free acids or free bases SUGEN, INC. (US) 2005-04-12 US disclosed
US-20030105151-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors SUGEN, INC. 2003-06-05 US disclosed
US-6395734-B1 ANTICANCER AGENTS SUGEN, INC. 2002-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105151-A1 Pyrrole substituted 2-indolinone protein kinase inhibitors DMPK, PDPK1, PLK2 ZAP70 503/4885PDGFRB 1086/4885FGFR1 930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.